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Acute brain injury induces a complicated cascade of deleter-
ious pathways that can be counteracted by therapeutic
hypothermia (TH) in the experimental setting [1]. While
there is no level I indication for TH in neurology, TH is in
principle useful for these indications if applied appropriately.
Ischemic stroke
While fever is harmful in acute stroke, no clinical study
showed improved outcome by antipyretic treatment –
most likely because of poor antipyretic management [1].
In large ischemic stroke, post-ischemic brain edema and
ICP are major therapeutic targets. A limited number of
case series indicate feasibility and safety of TH (48 to
72 hours) in large ischemic stroke. However, rewarming
led often to rebound of previously well controlled ICP
and hernation [1]. Knowing the natural course of edema
in large ischemic stroke, the duration of TH was chosen
too short to maintain appropriate ICP control. After pub-
lication of a successful randomized controlled trial for
hemicraniectomy in malignant stroke, TH might remain
an experimental therapeutic option in large ischemic
stroke which appears in more than the territory supplied
by the middle cerebral artery. In this case, TH and hemi-
craniectomy could be combined and TH should last
at least for more than 72 hours. Patients with acute
ischemic stroke (>6 hours from onset) might in principle
benefit from TH [1,2]. However, available data are lim-
ited and showed feasibility and safety of TH, but are
underpowered for efficacy. Ongoing stroke trials include
awake patients who are treated by an individual target
temperature of 36 to 33°C [2]. Shivering and discomfort
are counteracted by external warming and the use of
pharmacological agents (opioids, buspirone, or/and dex-
medetomidine). So far, both ongoing trials suffer from
slow recruitment which indicates the complex procedure.
Intracerebral hemorrhage
The outcome after large deep ICH is poor. Surgical and
medical treatment do not improve outcome essentially.
Beside the size of hematoma, the clinical condition is com-
plicated by perihemorrhagic edema, which increases over
more than 10 days [3]. Additionally, the size of perihemor-
rhagic edema is associated with the size of hematoma
volume. Two case series showed that early TH (35°C for
10 days) was feasible and safe. TH was able to control ICP
and prevented perihemorrhagic edema increase measured
by repeated cranial CT. Moreover, neurological outcome
and survival were superior compared with a historical con-
trol group [3]. At present, a German–Austrian controlled
randomized clinical trial investigates efficacy in large ICH.
Subarachnoid hemorrhage
Experimental data showed that TH was neuroprotective
in SAH and reduced vasospasm, DCI and brain edema.
Clinical data on the use of TH in SAH are limited. In a
recent study without a control group, TH was used as a
rescue therapy in patients with severe SAH and was feasi-
ble [4]. Smaller studies indicate that TH can reduce mean
blood flow velocity in vessels with vasospasm and poten-
tially improve outcome including less DCI.
In conclusion, TH is still a promising treatment option
for acute brain injury. The use of TH has to be adapted
to the specific targets of each condition and transferred
to clinical studies.
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